{
    "2021-10-26": [
        [
            {
                "time": "",
                "original_text": "智飞生物：公司自主研发项目冻干人用狂犬病疫苗（MRC-5细胞）正处于Ⅲ期临床试验过程中",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "自主研发",
                        "冻干人用狂犬病疫苗",
                        "MRC-5细胞",
                        "Ⅲ期临床试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "智飞生物：公司自主研发项目流感病毒裂解疫苗已完成临床试验",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "自主研发",
                        "流感病毒裂解疫苗",
                        "临床试验完成"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "智飞生物：公司和中科院微生物研究所合作研发的重组新型冠状病毒疫苗（CHO细胞）达到WHO要求的新冠疫苗有效性标准",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "中科院微生物研究所",
                        "重组新型冠状病毒疫苗",
                        "CHO细胞",
                        "WHO标准"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "新冠疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "智飞生物：公司的营销网络实现覆盖全国31个省、自治区、直辖市",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "营销网络",
                        "全国覆盖",
                        "31个省市区"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药",
                        "市场拓展"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}